Anti-Hypertensive Activity of Some Selected Unani Formulations: An Evidence-Based Approach for Verification of

Md Adil Shaharyar1, Rudranil Bhowmik1, Obaid Afzal2

  • 1Bioequivalence Study Centre, Department of Pharmaceutical Technology, Jadavpur University, Kolkata 700032, West Bengal, India.

Insights

This study investigated Unani formulations for hypertension using the L-NAME model. DMM formulation significantly reduced systolic blood pressure and plasma nitrite, suggesting potential anti-hypertensive activity via NO inhibition.

Area of Science:

  • Pharmacology
  • Cardiovascular Research
  • Traditional Medicine

Background:

  • Systemic arterial hypertension is a major global risk factor for cardiovascular disease (CVD) and mortality.
  • The World Health Organization recognizes Unani medicine as an alternative system of medicine.
  • Identifying effective anti-hypertensive agents is crucial for public health.

Purpose of the Study:

  • To evaluate the anti-hypertensive effects of selected Unani formulations.
  • To investigate the efficacy of these formulations in an L-NAME induced hypertension model.
  • To explore potential mechanisms of action, including effects on plasma biomarkers.

Main Methods:

  • The study utilized the L-NAME model to induce hypertension in rats.
  • Six groups were treated with different Unani formulations (KAS, DMM, MSR, HJ, KGS) or vehicle.
  • Systolic blood pressure, RR-interval, and plasma levels of sodium, potassium, nitrite, ANP, adrenaline, noradrenaline, and aldosterone were measured using LC-MS/MS.

Main Results:

  • The DMM formulation significantly reduced systolic blood pressure (p < 0.05) and plasma nitrite levels.
  • KAS, MSR, and HJ formulations showed non-significant reductions in systolic blood pressure.
  • KGS formulation increased systolic blood pressure, while DMM and KGS significantly increased potassium levels. Adrenaline and noradrenaline levels also changed significantly with DMM and KGS treatments.

Conclusions:

  • The Unani formulation DMM demonstrated significant anti-hypertensive activity, potentially mediated through nitric oxide (NO) inhibition.
  • Other formulations (KAS, MSR, HJ) showed minimal effects, while KGS may act through central sympathomimetic mechanisms.
  • Further research into DMM's anti-hypertensive properties and mechanisms is warranted.

Related Concept Videos

Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
46
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
806
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
34